Medclair Blog

MEOPA: the Center of a Growing Debate

Written by Jeta Smids | Dec 1, 2025 12:00:00 PM

INRS provides an overview of current methods for measuring MEOPA exposure, published on their official YouTube channel.

For years, MEOPA — a 50/50 mix of oxygen and nitrous oxide — has been a cornerstone of pain and anxiety management in French healthcare, as well as in many clinical settings worldwide. It’s widely used in emergency departments, pediatrics, dental care, and short procedures thanks to its reliability, rapid effect, and ease of administration.

But in recent years, MEOPA has moved from being an established norm in clinical care to becoming a topic of national debate. The conversation has shifted, especially in France, from how useful it is for patients to how safe it is for healthcare workers who handle it every day.

This shift was highlighted in a recent INRS webinar, “Soins sous MEOPA: Prévenir l’exposition professionnelle au protoxyde d’azote” — an event focused on occupational exposure for healthcare workers and the need for better prevention strategies in hospitals.

Why MEOPA Is Being Questioned

The active component in MEOPA — nitrous oxide (N₂O) — is invisible, odorless, and easy to underestimate. INRS notes that the risks associated with MEOPA are not always fully recognised in all clinical environments, and staff may occasionally be exposed to higher N₂O levels without being aware of it. 

Long-term exposure has been associated with a range of potential health effects, underscoring the importance of monitoring and prevention.
The issue isn’t MEOPA itself — it’s uncontrolled exposure.


Lack of Binding Exposure Limits

Unlike several other European countries, France still has no legally binding occupational exposure limit for nitrous oxide. Recommended reference levels exist, but they aren’t enforceable.
This regulatory gap fuels the debate: Are hospitals doing enough to protect staff?
The INRS conference clearly indicated growing national attention on the issue.

Occupational exposure and preventive measures

As hospitals begin to take N₂O exposure more seriously, new tools are emerging to support this transition. During the webinar, the speakers highlighted the need for continuous, personal monitoring — a gap that has been repeatedly emphasized in INRS guidance.

Medclair is one of the companies gaining increasing attention in France for addressing this need. Their personal nitrous oxide monitor, used in multiple French pilot studies and specifically mentioned in the webinar, provides real-time exposure tracking and alerts staff when concentrations rise. This type of wearable detection directly addresses what INRS identifies as a missing link: many risks remain invisible simply because exposure is not measured.

By giving clinical staff clear, objective data on what they are actually exposed to during everyday work, devices like these help hospitals pinpoint problem areas, validate preventive measures, and ensure that safety protocols deliver measurable results.


A Sector in Transition

The conversation around MEOPA in France reflects a broader shift in healthcare:
patient comfort remains essential, but staff safety must be equally prioritized.
With rising awareness — and events like the INRS webinar putting the issue in the spotlight — France is clearly moving toward a more proactive approach to MEOPA safety.

The debate isn’t about removing MEOPA from care — it’s about using it responsibly, with full awareness of the risks for those who administer it.
As new technologies, such as Medclair’s monitoring solutions, become part of the conversation, the path forward is becoming clearer:
safer for staff, controlled for the environment, and still beneficial for patients.

If you want to learn how real-time monitoring can support your organisation, reach out to Medclair to explore the solutions available today.

Contact us!

Links: 
https://meopa2025.inrs.fr/   
https://www.medclair.com/le-detecteur-de-protoxyde